Roche Holding AG joined peers in striking a cautious note on 2011 as it also grapples with US healthcare reforms and a push in Europe for lower drug prices.
The world's largest maker of cancer drugs, which is looking to cut costs after a string of product setbacks, just fell short of forecasts with a 4% rise in core earnings per share for 2010 as sales growth of top-selling cancer drug Avastin waned. In local currencies, earnings rose 10%.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
